Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Thoracic Surgery, Xinchang County People's Hospital, Xinchang, China.
J Immunother. 2024 Oct 1;47(8):313-322. doi: 10.1097/CJI.0000000000000535. Epub 2024 Jul 15.
Tumor immunotherapy has recently gained popularity as a cancer treatment strategy. The molecular mechanism controlling immune infiltration in lung adenocarcinoma (LUAD) cells, however, is not well characterized. Investigating the immune infiltration modulation mechanism in LUAD is crucial. LUAD patient samples were collected, and HES6 expression and immune infiltration level of CD8 + T cells in patient tissues were analyzed. Bioinformatics was utilized to identify binding relationship between E2F1 and HES6, and enrichment pathway of HES6. The binding of E2F1 to HES6 was verified using dual-luciferase and ChIP experiments. HES6 and E2F1 expression in LUAD cells was detected. LUAD cells were co-cultured with CD8 + T cells, and the CD8 + T cell killing level, IFN-γ secretion, and CD8 + T-cell chemotaxis level were measured. Expression of key genes involved in oxidative phosphorylation was detected, and the oxygen consumption rate of LUAD cells was assessed. A mouse model was constructed to assay Ki67 expression and apoptosis in tumor tissue. High expression of HES6 promoted CD8 + T-cell infiltration and enhanced T-cell killing ability through oxidative phosphorylation. Further bioinformatics analysis, molecular experiments, and cell experiments verified that E2F1 negatively regulated HES6 by oxidative phosphorylation, which suppressed CD8 + T-cell immune infiltration. In addition, in vivo assays illustrated that silencing HES6 repressed tumor cell immune evasion. E2F1 inhibited HES6 transcription, thereby mediating oxidative phosphorylation to suppress immune infiltration of CD8 + T cells in LUAD. The biological functions and signaling pathways of these genes were analyzed, which may help to understand the possible mechanisms regulating immune infiltration in LUAD.
肿瘤免疫疗法最近作为癌症治疗策略受到关注。然而,控制肺腺癌(LUAD)细胞免疫浸润的分子机制尚未得到很好的描述。研究 LUAD 中免疫浸润的调节机制至关重要。收集 LUAD 患者样本,分析患者组织中 CD8+T 细胞的 HES6 表达和免疫浸润水平。利用生物信息学方法鉴定 E2F1 与 HES6 的结合关系及 HES6 的富集通路。通过双荧光素酶和 ChIP 实验验证 E2F1 与 HES6 的结合。检测 LUAD 细胞中 HES6 和 E2F1 的表达。将 LUAD 细胞与 CD8+T 细胞共培养,检测 CD8+T 细胞的杀伤水平、IFN-γ 分泌水平和 CD8+T 细胞趋化水平。检测参与氧化磷酸化的关键基因的表达,并评估 LUAD 细胞的耗氧率。构建小鼠模型,检测肿瘤组织中 Ki67 的表达和细胞凋亡。高表达 HES6 通过氧化磷酸化促进 CD8+T 细胞浸润,增强 T 细胞杀伤能力。进一步的生物信息学分析、分子实验和细胞实验验证了 E2F1 通过氧化磷酸化负调控 HES6,抑制 CD8+T 细胞免疫浸润。此外,体内实验表明,沉默 HES6 抑制肿瘤细胞的免疫逃避。E2F1 抑制 HES6 转录,从而介导氧化磷酸化抑制 LUAD 中 CD8+T 细胞的免疫浸润。分析这些基因的生物学功能和信号通路,可能有助于理解调节 LUAD 中免疫浸润的可能机制。